N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide
CAS: 253168-86-4
Ref. 3D-DKA16886
2mg | Descontinuado | ||
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado | ||
100mg | Descontinuado | ||
250mg | Descontinuado | ||
500mg | Descontinuado |
Informação sobre produto
Apremilast is a prodrug that is converted in vivo to its active form. It inhibits the production of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), which are inflammatory cytokines. Apremilast is also an inhibitor of phosphodiesterase 4 (PDE4), which degrades cyclic adenosine monophosphate (cAMP). This drug has been shown to be effective in the treatment of arthritis, with pain relief after two weeks and improvement in joint mobility after four weeks. Apremilast is available as a racemate, with enantiomers having different pharmacological properties. The most potent form of apremilast is the S(-) enantiomer, which has been shown to be more potent than the R(+) enantiomer for inhibition of TNF-α and IL-1β.